JPRN-UMIN000003675
Completed
未知
Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer - Impact of functional imaging on the evaluation of treatment effect after neoadjuvant chemoradiation therapy for non-small cell lung cancer
niversity of Tokushima0 sites20 target enrollmentMay 31, 2010
Conditionson-Small Cell Lung Cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- on-Small Cell Lung Cancer
- Sponsor
- niversity of Tokushima
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Malignant pleuritis or malignant pericarditis. 2\.Pleural dissemination. 3\.Patients with severe complications. a.Pulmonary fibrosis. b.Severe heart disease.(Uncontrollable angina or myocardial infarction within the past 3 months) c.Uncontrollable Diabetes Mellitus. d.Severe infectious disease e.Other unsuitable patient judged by a physician. 4\.Women during pregnancy or lactating.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Examining methods to support self-guided attentional bias modification for alcohol consumption in young adultsExcess alcohol consumptionMental Health - AddictionACTRN12622000985785Queensland University of Technology (QUT)102
Active, not recruiting
Phase 1
Phase 2a open label study of Fovista¿ (anti-PDGF agent) administered in combination with anti-VEGF therapy in subjects previously treated or treatment-naive.Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2015-000519-42-ITIVERIC bio, Inc.32
Active, not recruiting
Phase 1
Role of imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapySubfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 18.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: LLT Classification code 10067791 Term: Wet macular degeneration System Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]EUCTR2015-000519-42-FROPHTHOTECH CORPORATIO32
Active, not recruiting
Phase 1
Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersse of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - InvestigationsEUCTR2008-003597-18-GBAvid Radiopharmaceuticals, Inc34
Completed
Phase 2
Amyloid imaging in Alzheimer's disease, frontotemporal dementia and healthy volunteersFrontotemporal dementia and Alzheimer's diseaseNervous System DiseasesAlzheimer's diseaseISRCTN58435532Avid Radiopharmaceuticals Inc.40